Skye Bioscience (SKYE) grants CEO 280,000 stock options at $0.82

Rhea-AI Filing Summary

Skye Bioscience Chief Executive Officer and director Punit Dhillon reported a grant of stock options. On February 6, 2026, he was awarded an option to buy 280,000 shares of common stock at an exercise price of $0.82 per share, held directly.

The option vests in equal monthly installments over a four-year period beginning January 19, 2026 and expires on February 6, 2036. Following this grant, Dhillon beneficially owns 280,000 derivative securities in the form of this stock option.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider DHILLON PUNIT

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	280,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 280,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DHILLON PUNIT

(Last) (First) (Middle)

11250 EL CAMINO REAL, SUITE 100

C/O SKYE BIOSCIENCE, INC.

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Skye Bioscience, Inc. [ SKYE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.82	02/06/2026		A		280,000		(1)	02/06/2036	Common Stock	280,000	$0	280,000	D

Explanation of Responses:

1. The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026.

Remarks:

	/s/ Kaitlyn Arsenault, as Attorney-in-Fact	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Skye Bioscience (SKYE) report on this Form 4?

Skye Bioscience reported a stock option grant to CEO and director Punit Dhillon. He received options covering 280,000 shares of common stock, recorded as an acquisition of derivative securities with no purchase price paid for the option itself.

What are the key terms of Punit Dhillon’s new Skye Bioscience stock options?

Punit Dhillon’s options allow him to buy 280,000 Skye Bioscience common shares at an exercise price of $0.82 per share. The options are held directly, with a listed expiration date of February 6, 2036, providing a long-term incentive window.

How do the Skye Bioscience CEO’s options vest according to this filing?

The filing states the stock option vests in equal monthly installments over four years beginning January 19, 2026. This means a portion of the 280,000-share option becomes exercisable each month throughout the four-year vesting schedule.

How many Skye Bioscience derivative securities does the CEO own after this transaction?

After the reported transaction, Punit Dhillon beneficially owns 280,000 derivative securities in the form of this stock option. The Form 4 shows this entire amount as directly owned following the grant on February 6, 2026.

What transaction code is used for the Skye Bioscience CEO’s option grant?

The transaction is coded as “A,” indicating an acquisition of derivative securities. It reflects the grant of a stock option to buy 280,000 Skye Bioscience common shares, rather than a market purchase or sale of existing shares.